Adhera Therapeutics, Inc. (ATRX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2022 | 79 Thousand USD | -59.69% |
| 2021 | 196 Thousand USD | 19500.0% |
| 2020 | 1000.00 USD | -99.76% |
| 2019 | 420 Thousand USD | -91.83% |
| 2018 | 5.14 Million USD | -16.87% |
| 2017 | 6.18 Million USD | -0.04% |
| 2016 | 6.18 Million USD | -18.55% |
| 2015 | 7.59 Million USD | -17.59% |
| 2014 | 9.21 Million USD | 19.04% |
| 2013 | 7.74 Million USD | 3.88% |
| 2012 | 7.45 Million USD | -36.57% |
| 2011 | 11.75 Million USD | -60.09% |
| 2010 | 29.44 Million USD | 307.29% |
| 2009 | 7.22 Million USD | -44.97% |
| 2008 | 13.13 Million USD | -78.68% |
| 2007 | 61.61 Million USD | -16.55% |
| 2006 | 73.83 Million USD | 1.2% |
| 2005 | 72.95 Million USD | -9.68% |
| 2004 | 80.77 Million USD | 159.41% |
| 2003 | 31.13 Million USD | 35.09% |
| 2002 | 23.05 Million USD | 49.29% |
| 2001 | 15.44 Million USD | 32.41% |
| 2000 | 11.66 Million USD | -42.27% |
| 1999 | 20.2 Million USD | -26.55% |
| 1998 | 27.5 Million USD | 0.36% |
| 1997 | 27.4 Million USD | 112.4% |
| 1996 | 12.9 Million USD | 37.23% |
| 1995 | 9.4 Million USD | 56.67% |
| 1994 | 6 Million USD | 700.0% |
| 1993 | 750 Thousand USD | 53.06% |
| 1992 | 490 Thousand USD | -27.94% |
| 1991 | 680 Thousand USD | -12.82% |
| 1990 | 780 Thousand USD | 18.18% |
| 1989 | 660 Thousand USD | 37.5% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q1 | 104 Thousand USD | 31.65% |
| 2023 Q3 | 44.07 Thousand USD | -46.25% |
| 2023 Q2 | 82 Thousand USD | -21.15% |
| 2022 Q1 | 170 Thousand USD | -13.27% |
| 2022 Q3 | 256 Thousand USD | -73.77% |
| 2022 FY | 79 Thousand USD | -59.69% |
| 2022 Q2 | 976 Thousand USD | 474.12% |
| 2022 Q4 | 79 Thousand USD | -69.14% |
| 2021 Q1 | 1000.00 USD | 0.0% |
| 2021 Q3 | 151 Thousand USD | 259.52% |
| 2021 Q4 | 196 Thousand USD | 29.8% |
| 2021 FY | 196 Thousand USD | 19500.0% |
| 2021 Q2 | 42 Thousand USD | 4100.0% |
| 2020 FY | 1000.00 USD | -99.76% |
| 2020 Q1 | 315 Thousand USD | -25.0% |
| 2020 Q2 | 152 Thousand USD | -51.75% |
| 2020 Q3 | 54 Thousand USD | -64.47% |
| 2020 Q4 | 1000.00 USD | -98.15% |
| 2019 Q2 | 2.75 Million USD | -15.69% |
| 2019 FY | 420 Thousand USD | -91.83% |
| 2019 Q1 | 3.26 Million USD | -36.41% |
| 2019 Q4 | 420 Thousand USD | -89.85% |
| 2019 Q3 | 4.13 Million USD | 50.07% |
| 2018 FY | 5.14 Million USD | -16.87% |
| 2018 Q2 | 14.46 Million USD | 137.86% |
| 2018 Q1 | 6.08 Million USD | -1.64% |
| 2018 Q3 | 8.29 Million USD | -42.64% |
| 2018 Q4 | 5.14 Million USD | -38.05% |
| 2017 Q2 | 6.63 Million USD | 8.42% |
| 2017 Q1 | 6.11 Million USD | -1.12% |
| 2017 Q4 | 6.18 Million USD | -0.99% |
| 2017 Q3 | 6.24 Million USD | -5.84% |
| 2017 FY | 6.18 Million USD | -0.04% |
| 2016 Q1 | 7.17 Million USD | -5.49% |
| 2016 Q2 | 7.14 Million USD | -0.45% |
| 2016 Q3 | 6.88 Million USD | -3.72% |
| 2016 Q4 | 6.18 Million USD | -10.08% |
| 2016 FY | 6.18 Million USD | -18.55% |
| 2015 Q2 | 7.55 Million USD | -6.13% |
| 2015 Q3 | 8.12 Million USD | 7.53% |
| 2015 Q4 | 7.59 Million USD | -6.5% |
| 2015 Q1 | 8.04 Million USD | -12.68% |
| 2015 FY | 7.59 Million USD | -17.59% |
| 2014 Q2 | 11.1 Million USD | -10.16% |
| 2014 Q4 | 9.21 Million USD | -7.45% |
| 2014 FY | 9.21 Million USD | 19.04% |
| 2014 Q1 | 12.35 Million USD | 59.61% |
| 2014 Q3 | 9.95 Million USD | -10.3% |
| 2013 FY | 7.74 Million USD | 3.88% |
| 2013 Q4 | 7.74 Million USD | 8.01% |
| 2013 Q3 | 7.16 Million USD | 4.52% |
| 2013 Q2 | 6.85 Million USD | -0.52% |
| 2013 Q1 | 6.89 Million USD | -7.5% |
| 2012 Q1 | 10.67 Million USD | -9.11% |
| 2012 Q2 | 10.18 Million USD | -4.63% |
| 2012 FY | 7.45 Million USD | -36.57% |
| 2012 Q3 | 8.01 Million USD | -21.33% |
| 2012 Q4 | 7.45 Million USD | -6.99% |
| 2011 Q3 | 28.13 Million USD | -12.64% |
| 2011 Q1 | 29.12 Million USD | -1.08% |
| 2011 FY | 11.75 Million USD | -60.09% |
| 2011 Q2 | 32.2 Million USD | 10.58% |
| 2011 Q4 | 11.75 Million USD | -58.24% |
| 2010 Q1 | 8.59 Million USD | 18.92% |
| 2010 FY | 29.44 Million USD | 307.29% |
| 2010 Q4 | 29.44 Million USD | 307.29% |
| 2010 Q3 | 7.22 Million USD | 9.31% |
| 2010 Q2 | 6.61 Million USD | -23.08% |
| 2009 FY | 7.22 Million USD | -44.97% |
| 2009 Q1 | 15.37 Million USD | 17.0% |
| 2009 Q2 | 15.73 Million USD | 2.37% |
| 2009 Q3 | 9.97 Million USD | -36.6% |
| 2009 Q4 | 7.22 Million USD | -27.54% |
| 2008 Q1 | 43.46 Million USD | -29.45% |
| 2008 Q4 | 13.13 Million USD | -38.21% |
| 2008 FY | 13.13 Million USD | -78.68% |
| 2008 Q3 | 21.26 Million USD | -38.15% |
| 2008 Q2 | 34.37 Million USD | -20.92% |
| 2007 Q1 | 103.15 Million USD | 39.71% |
| 2007 Q2 | 91.65 Million USD | -11.15% |
| 2007 Q3 | 78.41 Million USD | -14.44% |
| 2007 Q4 | 61.61 Million USD | -21.43% |
| 2007 FY | 61.61 Million USD | -16.55% |
| 2006 Q1 | 78.31 Million USD | 7.34% |
| 2006 Q4 | 73.83 Million USD | -4.93% |
| 2006 FY | 73.83 Million USD | 1.2% |
| 2006 Q2 | 81.21 Million USD | 3.71% |
| 2006 Q3 | 77.66 Million USD | -4.37% |
| 2005 Q4 | 72.95 Million USD | -6.97% |
| 2005 FY | 72.95 Million USD | -9.68% |
| 2005 Q3 | 78.41 Million USD | 26.67% |
| 2005 Q2 | 61.9 Million USD | -7.46% |
| 2005 Q1 | 66.89 Million USD | -17.19% |
| 2004 FY | 80.77 Million USD | 159.41% |
| 2004 Q4 | 80.77 Million USD | 167.06% |
| 2004 Q3 | 30.24 Million USD | -5.49% |
| 2004 Q2 | 32 Million USD | 24.22% |
| 2004 Q1 | 25.76 Million USD | -17.26% |
| 2003 Q1 | 30.91 Million USD | 34.1% |
| 2003 Q2 | 33.34 Million USD | 7.88% |
| 2003 FY | 31.13 Million USD | 35.09% |
| 2003 Q4 | 31.13 Million USD | -15.95% |
| 2003 Q3 | 37.04 Million USD | 11.1% |
| 2002 Q3 | 28.53 Million USD | 16.53% |
| 2002 Q2 | 24.48 Million USD | 9.26% |
| 2002 Q1 | 22.4 Million USD | 45.14% |
| 2002 FY | 23.05 Million USD | 49.29% |
| 2002 Q4 | 23.05 Million USD | -19.21% |
| 2001 Q2 | 12.02 Million USD | -11.71% |
| 2001 FY | 15.44 Million USD | 32.41% |
| 2001 Q4 | 15.44 Million USD | 35.23% |
| 2001 Q3 | 11.41 Million USD | -5.07% |
| 2001 Q1 | 13.62 Million USD | 16.83% |
| 2000 Q3 | 13.21 Million USD | -9.34% |
| 2000 Q1 | 16.34 Million USD | -19.09% |
| 2000 FY | 11.66 Million USD | -42.27% |
| 2000 Q4 | 11.66 Million USD | -11.78% |
| 2000 Q2 | 14.58 Million USD | -10.79% |
| 1999 Q2 | 23.9 Million USD | -6.64% |
| 1999 FY | 20.2 Million USD | -26.55% |
| 1999 Q3 | 22.1 Million USD | -7.53% |
| 1999 Q4 | 20.2 Million USD | -8.6% |
| 1999 Q1 | 25.6 Million USD | -6.91% |
| 1998 FY | 27.5 Million USD | 0.36% |
| 1998 Q3 | 28.8 Million USD | -0.69% |
| 1998 Q4 | 27.5 Million USD | -4.51% |
| 1998 Q2 | 29 Million USD | 7.41% |
| 1998 Q1 | 27 Million USD | -1.46% |
| 1997 Q4 | 27.4 Million USD | -4.2% |
| 1997 Q3 | 28.6 Million USD | -4.03% |
| 1997 Q2 | 29.8 Million USD | -1.65% |
| 1997 Q1 | 30.3 Million USD | 0.0% |
| 1997 FY | 27.4 Million USD | 112.4% |
| 1996 Q2 | 9.4 Million USD | 62.07% |
| 1996 Q1 | 5.8 Million USD | 3.57% |
| 1996 FY | 12.9 Million USD | 37.23% |
| 1996 Q3 | 8.7 Million USD | -7.45% |
| 1995 Q3 | 6 Million USD | -36.17% |
| 1995 FY | 9.4 Million USD | 56.67% |
| 1995 Q1 | 5.9 Million USD | 1.72% |
| 1995 Q2 | 9.4 Million USD | 59.32% |
| 1995 Q4 | 5.6 Million USD | -6.67% |
| 1994 Q4 | 5.8 Million USD | -1.69% |
| 1994 FY | 6 Million USD | 700.0% |
| 1994 Q1 | 5.7 Million USD | -1.72% |
| 1994 Q2 | 6 Million USD | 5.26% |
| 1994 Q3 | 5.9 Million USD | -1.67% |
| 1993 FY | 750 Thousand USD | 53.06% |
| 1993 Q4 | 5.8 Million USD | 427.27% |
| 1993 Q3 | 1.1 Million USD | 0.0% |
| 1992 FY | 490 Thousand USD | -27.94% |
| 1991 FY | 680 Thousand USD | -12.82% |
| 1990 FY | 780 Thousand USD | 18.18% |
| 1989 FY | 660 Thousand USD | 37.5% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 10.55 Million USD | 99.251% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 89.749% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 85.692% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 83.561% |
| Qrons Inc. | 420.00 USD | -18709.524% |
| Rebus Holdings, Inc. | 5000.00 USD | -1480.0% |
| Skye Bioscience, Inc. | 11.94 Million USD | 99.338% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.939% |
| Adynxx, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -3319.913% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 99.717% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 88.509% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 95.966% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 99.797% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 98.906% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -3.465% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.926% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 94.483% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -9.169% |
| Mesoblast Limited | 667.9 Million USD | 99.988% |
| Marizyme, Inc. | 22.01 Million USD | 99.641% |
| Genus plc | 1.02 Billion USD | 99.992% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 94.184% |
| Pharming Group N.V. | 462.85 Million USD | 99.983% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 97.615% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 84.17% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 87.4% |
| ContraFect Corporation | 20.67 Million USD | 99.618% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 79.763% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 79.329% |
| IMV Inc. | 31.33 Million USD | 99.748% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 98.095% |
| MultiCell Technologies, Inc. | 126.22 USD | -62489.13% |
| ONE Bio Corp. | 70.08 Million USD | 99.887% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 91.593% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.939% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | 81.701% |
| Q BioMed Inc. | 3.51 Million USD | 97.753% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 99.775% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | 69.764% |
| Biomind Labs Inc. | 73.81 Thousand USD | -7.019% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.982% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 94.547% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 99.737% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 97.123% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 96.965% |
| GB Sciences, Inc. | 103.44 Thousand USD | 23.629% |
| Alpha Cognition Inc. | 2.45 Million USD | 96.778% |
| HST Global, Inc. | 1526.00 USD | -5076.933% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 92.004% |
| Halberd Corporation | 10.13 Thousand USD | -679.785% |
| Enzolytics Inc. | 361.7 Million USD | 99.978% |
| Agentix Corp. | 261.39 Thousand USD | 69.777% |
| Resverlogix Corp. | 8.11 Million USD | 99.026% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 95.793% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.998% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.834% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 87.65% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -246.78% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 99.117% |
| AVAX Technologies, Inc. | 7.37 Million USD | 98.929% |
| Zenith Capital Corp. | 7410.00 USD | -966.127% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.998% |
| Ember Therapeutics, Inc. | 184.00 USD | -42834.783% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | 75.451% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | 69.774% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 91.487% |
| Kadimastem Ltd | 2.3 Million USD | 96.571% |
| Helix BioMedix, Inc. | 3.02 Million USD | 97.389% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.85% |
| BioStem Technologies, Inc. | 14.56 Million USD | 99.457% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -38.368% |
| LadRx Corporation | 2.3 Million USD | 96.577% |
| Cell Source, Inc. | 195.17 Thousand USD | 59.523% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 77.659% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 77.659% |
| NovAccess Global Inc. | 62.24 Thousand USD | -26.912% |
| Affymax, Inc. | 7.44 Million USD | 98.939% |
| Itoco Inc. | 1.4 Million USD | 94.357% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | 17.413% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | 25.472% |
| Mobile Lads Corp. | 52.00 USD | -151823.077% |
| CytoDyn Inc. | 11.13 Million USD | 99.291% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | 44.744% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -341.834% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 79.506% |
| SYBLEU INC | 330.46 Thousand USD | 76.095% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 80.705% |
| International Stem Cell Corporation | 5.39 Million USD | 98.534% |
| Bioxytran, Inc. | 137.63 Thousand USD | 42.603% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 99.473% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 99.523% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 90.864% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 98.949% |
| Neutra Corp. | 2851.00 USD | -2670.958% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 99.756% |
| PureTech Health plc | 693.97 Million USD | 99.989% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 99.021% |
| IXICO plc | 15.84 Million USD | 99.501% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 99.046% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.924% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Cellectis S.A. | 333.99 Million USD | 99.976% |